Savara Inc (NASDAQ:SVRA) — Market Cap & Net Worth
Market Cap & Net Worth: Savara Inc (SVRA)
Savara Inc (NASDAQ:SVRA) has a market capitalization of $1.04 Billion ($1.04 Billion) as of April 27, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8929 globally and #2391 in its home market, demonstrating a -9.22% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Savara Inc's stock price $5.12 by its total outstanding shares 203467845 (203.47 Million).
Savara Inc Market Cap History: 2015 to 2026
Savara Inc's market capitalization history from 2015 to 2026. Data shows change from $5.99 Billion to $1.04 Billion (-16.55% CAGR).
Index Memberships
Savara Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.04% | #239 of 976 |
|
NASDAQ Composite
IXIC
|
$38.14 Trillion | 0.00% | #913 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.06% | #143 of 263 |
Weight: Savara Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Savara Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Savara Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
252300.13x
Savara Inc's market cap is 252300.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.99 Billion | $54.00 | -$39.84 Million | 110856064.22x | N/A |
| 2016 | $1.24 Billion | $400.00K | -$10.92 Million | 3090.68x | N/A |
| 2020 | $233.99 Million | $257.00K | -$49.62 Million | 910.46x | N/A |
| 2021 | $252.30 Million | $1.00K | -$43.01 Million | 252300.13x | N/A |
Competitor Companies of SVRA by Market Capitalization
Companies near Savara Inc in the global market cap rankings as of April 27, 2026.
Key companies related to Savara Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $109.17 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #336 globally with a market cap of $78.09 Billion USD.
- UCB SA (BR:UCB): Ranked #511 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #571 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.17 Billion | $430.29 |
| #336 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.09 Billion | $751.57 |
| #511 | UCB SA | BR:UCB | $51.74 Billion | €239.00 |
| #571 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Savara Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Savara Inc's market cap moved from $5.99 Billion to $ 1.04 Billion, with a yearly change of -16.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.04 Billion | -15.09% |
| 2025 | $1.23 Billion | +96.42% |
| 2024 | $624.65 Million | -34.68% |
| 2023 | $956.30 Million | +203.23% |
| 2022 | $315.38 Million | +25.00% |
| 2021 | $252.30 Million | +7.83% |
| 2020 | $233.99 Million | -74.33% |
| 2019 | $911.54 Million | -40.82% |
| 2018 | $1.54 Billion | -48.99% |
| 2017 | $3.02 Billion | +144.24% |
| 2016 | $1.24 Billion | -79.35% |
| 2015 | $5.99 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 27th, 2026 the market cap of Savara Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.04 Billion USD |
| MoneyControl | $1.04 Billion USD |
| MarketWatch | $1.04 Billion USD |
| marketcap.company | $1.04 Billion USD |
| Reuters | $1.04 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.